PFCD advocates equitable insurance coverage for Robotic Joint Replacement amid India’s arthritis burden: Our Bureau, Mumbai ...
Our Bureau, Bengaluru Wednesday, October 8, 2025, 17:15 Hrs [IST] ...
MicroRNAs: Following a single 4-hour HP treatment, decreases were observed in seven out of ten miRNAs examined in two of the three participants. MicroRNAs are one component of the cargo of ...
BlueRock Therapeutics reports positive 36-month results from phase I trial of bemdaneprocel for treating Parkinson’s disease: Berlin, Germany Wednesday, October 8, 2025, 18:00 H ...
Salipro Biotech strengthens global IP portfolio with two new Japanese patents: Stockholm, Sweden Wednesday, October 8, 2025, 14:00 Hrs [IST] Salipro Biotech AB, a pioneering biote ...
NephroPlus, Asia’s largest dialysis service provider as per the Frost & Sullivan Report, 2025, has achieved a historic milestone by crossing 500 centres globally. Marking this achievement, the company ...
AstraZeneca announces baxdrostat meets the primary endpoint in Bax24 phase III trial in patients with resistant hypertension: Cambridge, UK Wednesday, October 8, 2025, 12:00 Hrs [ ...
Our Bureau, Chennai Wednesday, October 8, 2025, 12:40 Hrs [IST] ...
General Atlantic Singapore RR transfers 2.25% of its Rubicon Research holding amounting to approx. Rs. 169 crore: Our Bureau, Mumbai Wednesday, October 8, 2025, 14:45 Hrs [IST] Ge ...
Geneva Wednesday, October 8, 2025, 10:00 Hrs [IST] WHO has launched the Global Clinical Trials Forum (GCTF), a global, multi-stakeho ...
Eisai introduces Leqembi Iqlik in US as maintenance dosing regimen to treat Alzheimer’s disease: Stockholm Wednesday, October 8, 2025, 15:00 Hrs [IST] BioArctic AB’s (publ) pa ...
Daiichi Sankyo submits sNDA to Japan’s MHLW for Enhertu plus pertuzumab to treat patients with HER2 positive unresectable or recurrent breast cancer: Tokyo Wednesday, October 8, ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback